UK markets closed

argenx SE (ARGNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
357.000.00 (0.00%)
At close: 10:40AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close357.00
BidN/A x N/A
AskN/A x N/A
Day's range357.00 - 357.00
52-week range130.00 - 357.00
Avg. volume8
Market cap24.869B
Beta (5Y monthly)1.03
PE ratio (TTM)N/A
EPS (TTM)-11.53
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

    Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing authorization application (MAA) expected in approximately 60 days If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG) Breda, the Netherlands—June 24, 2022—argenx (Eur

  • Globe Newswire

    argenx to Present at Upcoming Investor Conferences

    June 1, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in June: Jefferies 2022 Global Healthcare Conference. Fireside chat on Wednesday, June 8, 2022 at 1:00 p.m. ET in New York, NY.Goldman Sachs 43rd Annual Global Healthcare Conference. Fireside chat on Wednesday, Jun

  • Globe Newswire

    argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis

    Positive scientific opinion under Early Access to Medicines Scheme (EAMS) will make efgartigimod available to eligible generalized myasthenia gravis (gMG) patients in the UK prior to marketing authorization Efgartigimod was granted a Promising Innovative Medicine (PIM) designation by UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in November 2021 Breda, the Netherlands—May 31, 2022—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives